Clarification Statement

2021-01-31

Sinovac Biotech Ltd. (“Sinovac”) today learned of an English-language statement that was purportedly made in the name of Sinovac. This fraudulent statement (“Fraudulent Statement”) was in no way made or authorized by Sinovac, nor does it reflect the views of Sinovac. The Fraudulent Statement was sent to certain media outlets in Brazil on 30 January 2020, disguised as a valid statement from Sinovac. A number of media have reported about the Fraudulent Statement.

With regard to this, we hereby clarify that:

(i) Abernathy MacGregor is the sole media relation consultant engaged by Sinovac or authorized to communicate or issue statements on its behalf. Sinovac has never authorized or engaged any other company or individual to carry out any public relations activities on behalf of Sinovac.

(ii) Sinovac has never made or issued or engaged any individual or organization to make or issue the Fraudulent Statement.

Sinovac believes that the global fight against the COVID-19 pandemic requires unity and a coordinated response. All of the companies and organizations committed to fighting the pandemic are contributing partners, not competitors.

We oppose any malicious degrading for defamation. Sinovac wishes to condemn the fraudulent behaviors involved with the Fraudulent Statement and the sentiments therein, and reserves all rights to take actions to seek remedies and pursue liabilities against those who have made and published the Fraudulent Statement.

Sinovac Biotech Ltd.

Jan 31, 2021

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com